Scalper1 News
Cardiac-device giant Edwards Lifesciences (EW) issued 2016 guidance on the low side of estimates Wednesday, though it raised its long-term market estimate for a key product line. As it kicked off its annual investor day, Edwards affirmed its previous 2015 guidance and forecast next year’s sales at $2.5 billion to $2.75 billion. That represents growth of 7% to 11% from this year, excluding the foreign-exchange impact, and is in line with analysts’ Scalper1 News
Scalper1 News